Honasa Consumer to acquire 58% in Fluence Pharma for about Rs 135 Cr

Listed Co AcquisitionStrategic Transactions View source PDF

HONASA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-0.7%1-day move

₹420.00

prior close

₹429.05

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-2.3-2.6-3.9-5.1-0.7+5.8+9.0+11.0+11.3+11.7+11.6+6.7——

Up moveDown movePending

AI summary

Honasa Consumer (Mamaearth) board approved acquiring 58% stake in Fluence Pharma, a dermatologist-led nutraceuticals company, for an enterprise value of about Rs 135 Cr (around 3.4x FY26 revenue, 15x EBITDA). Remaining 42% to be bought in two tranches over 5-7 years. Fluence had FY26 revenue of about Rs 40 Cr with 20% plus EBITDA margin. Honasa will also incorporate wholly owned subsidiary Honasa Health for B2C nutraceuticals. Deal expected to close in 8 weeks. Aims to build a Rs 500 Cr nutraceuticals franchise.

Likely market impact

Entry into fast-growing nutraceuticals category via a Rs 135 Cr cash deal; positive for long-term growth but adds integration risk.